Lyell to highlight vision for its next-generation car t-cell therapy pipeline at 43rd annual jp morgan healthcare conference

South san francisco, calif., jan. 09, 2025 (globe newswire) -- lyell immunopharma, inc. (nasdaq: lyel), a clinical-stage company advancing a pipeline of next-generation car t-cell therapies for patients with cancer, today announced pipeline updates, including its plans to advance impt-314, a potentially best-in-class therapy for aggressive large b-cell lymphoma, into pivotal trials. impt-314 is an autologous dual-targeting cd19/cd20 chimeric antigen receptor (car) t-cell product candidate designed to increase complete response rates and prolong the duration of the responses as compared to the approved cd19‑targeted car therapies for the treatment of large b-cell lymphoma.
CAR Ratings Summary
CAR Quant Ranking